SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
NKTR Drug delivery Company
An SI Board Since September 2005
Posts SubjectMarks Bans Symbol
507 31 0 NKTR
Emcee:  david nordic Type:  Unmoderated
Introduction Market Data Compact
Subject 11419

Nektar Therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform.

Cancer and Pain Products
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
507NKTR181, to abort was the only *right* option. ir.nektar.comMiljenko Zuanic-1/15/2020
506I commented on the JPM Q&A session, including the "Competing CombinatioDewDiligence_on_SI-1/14/2020
505NKTR-BMY bempeg (214) amendment: <On January 9, 2020, Nektar Therapeutics, a Miljenko Zuanic11/10/2020
504MILs? There are too many acronyms already!DewDiligence_on_SI-12/19/2019
503<The FDA remains committed to addressing this national crisis on all fronts, Miljenko Zuanic-12/19/2019
502WindMIL Therapeutics Announces Clinical Research Collaboration with Bristol-MyerMiljenko Zuanic-12/19/2019
501Sanofi going after Synthrox (THOR), IL2 player. sanofi.comMiljenko Zuanic-12/9/2019
500RE: NKTR-255 Early, so it is on active screen: nektar.comMiljenko Zuanic-11/10/2019
499RE: NKTR358 (@ACR) PR: finance.yahoo.com Poster: nektar.com < subcutaneous doMiljenko Zuanic-11/10/2019
498Twitter is full of BS members. For no good reason I am blocked 50% of the timesMiljenko Zuanic111/10/2019
497Is there opening for IO-triple regime (PD1 + CTLA-4 + IL2), and chemo-sparing???Miljenko Zuanic-10/22/2019
496finance.yahoo.com Stephen Doberstein (chief-R&D, 181-inventor) is gently pMiljenko Zuanic-10/1/2019
495secfilings.nasdaq.com Why took him so long? Well, better ever than never...Miljenko Zuanic-9/10/2019
494Thanks Julius for complete institutions ownership report. I was rounding INVESCOMiljenko Zuanic-9/7/2019
493 Holder Shares Date Reported % Out Value Invesco Ltd. 23,343,019 Jun 29, 201Julius Wong-9/7/2019
492I did not commented early on this,... for 2Q INVESCO Ltd increased position by 2Miljenko Zuanic-9/7/2019
491Most likely there will be extension of the PDUFA, 3-6 months, and Adcom is very Miljenko Zuanic18/28/2019
490I guess technically I am not accurate in them saying it won't be met but howghmm-8/28/2019
489So, it appears there is no 181 CRL and path to approval is intact. MrM need updMiljenko Zuanic-8/28/2019
488FWIW they already announced PDUFA won't be met. That was CFO and he exerciseghmm-8/28/2019
487Unbelievable—-the CEO dumps another 30,000 shares four days before the FDA is scArthur Radley-8/26/2019
486What a waste of the options! SUCKERS!Miljenko Zuanic-8/19/2019
485CFO nets another $250;000.00 by flipping a option conversion into shares and selArthur Radley-8/17/2019
484Ah, well maybe they can amend that suit. Something to keep an eye on. Whatevertuck-8/9/2019
483<Mildly surprised no class action suit has been filed yet.> "On OctobMiljenko Zuanic-8/9/2019
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News